← Back to Search

Ultrasound-Guided Obturator Nerve Block for Ambulatory Hip Arthroscopy

N/A

Waitlist Available

Led By Francis Salinas, MD

Research Sponsored by Benaroya Research Institute

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up within 12-24 hours after discharge to home (from the hospital); typically the same night of the day of surgery.

Awards & highlights

All Individual Drugs Already Approved

Approved for 5 Other Conditions

Summary

Hip arthroscopy is commonly associated with moderate-to-severe postoperative pain. The purpose of this study is to investigate the analgesic efficacy of preoperative obturator nerve block as measured by postoperative pain scores and postoperative analgesic requirements. The primary outcome will be the patient's first reported pain scores in the post anesthesia care unit (PACU).

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ from the start of surgery to 24 hours after surgery complete (average surgical duration 2.5 hours).

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~from the start of surgery to 24 hours after surgery complete (average surgical duration 2.5 hours).

This trial's timeline: 3 weeks for screening, Varies for treatment, and from the start of surgery to 24 hours after surgery complete (average surgical duration 2.5 hours). for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Immediate pain score upon arrival to phase 1 PACU (NRS pain score)

Secondary study objectives

Nausea (Number of episodes of nausea and vomiting during the 1st 24 hours postoperatively)

Opioid (analgesic) consumption

Pain scores for the 1st 24 hours after surgery (Numeric Rating Scale Pain)

+2 more

Awards & Highlights

All Individual Drugs Already Approved

Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.

Approved for 5 Other Conditions

This treatment demonstrated efficacy for 5 other conditions.

Trial Design

2Treatment groups

Active Control

Placebo Group

Group I: Obturator nerve blockActive Control2 Interventions

Ultrasound-guided single-injection obturator nerve block with 20 mL ropivacaine 0.5%

Group II: Sham blockPlacebo Group2 Interventions

Placebo arm. Ultrasound-guided injection of 3-5 mL normal saline in the subcutaneous tissue in the same location as would for an obturator nerve block.

Do I qualify?Apply below to find out